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Abstract: A majority of hepatocellular carcinoma (HCC) develops in the setting of persistent chronic
inflammation as immunological mechanisms have been shown to play a vital role in the initiation,
growth and progression of tumours. The index review has been intended to highlight ongoing
immunological changes in the hepatic parenchyma responsible for the genesis and progression of
HCC. The in-situ vaccine effect of radiofrequency (RF) is through generation tumour-associated
antigens (TAAs), following necrosis and apoptosis of tumour cells, which not only re-activates
the antitumour immune response but can also act in synergism with checkpoint inhibitors to
generate a superlative effect with intent to treat primary cancer and distant metastasis. An improved
understanding of oncogenic responses of immune cells and their integration into signaling pathways
of the tumour microenvironment will help in modulating the antitumour immune response. Finally,
we analyzed contemporary literature and summarised the recent advances made in the field of
targeted immunotherapy involving checkpoint inhibitors along with RF application with the intent
to reinstate antitumour immunity and outline future directives in very early and early stages of HCC.
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1. Introduction
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy; according to
GLOBOCAN 2018 database, the figure of estimated annual incidence is approximately 841,000 and
mortality of 782,000, labeling the entity as the sixth most commonly encountered and fourth most
lethal cancer of the globe [1]. The HCC begins over the background of chronic inflammation of the
liver, which occurs owing to several attributes, notably hepatitis B virus (HBV) and hepatitis C virus
(HCV) infections and non-alcoholic steatohepatitis leading to cirrhosis [2–4].
Despite the recent advancement in the management of HCC, it continues to remain a significant
burden on global health owing to late presentation, higher recurrence and metastasis. The disease
prognosis is highly related to its stage at presentation; in an early stage with localised disease, hepatic
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resection or transplantation can be an option; a five-year survival is 40–70%; however, patients with
advanced disease that is not amenable to locoregional therapy have a median survival rate between
3–11 months [5–7].
HCCs are classical archetypes of inflammation-associated malignancy as these tumours are
arising in the context of hepatic inflammation and the resultant fibrosis. The risk factors of HCC
lead to a chronic inflammatory state and proclivities of proinflammatory cells present within the
tumour microenvironment engender carcinogenesis and dysregulated growth [8–10]; studies have
outlined that continued expression of cytokines and recruitment of immune cells on the background
of chronic inflammatory state cause DNA damage leading to genetic mutations and neoplastic
transformation [11–13].
Typically, the host immune system perceives and eliminates any aberrant changes; however,
that is not always the case and the inflammatory state of liver brings significant alteration in the
tumour microenvironment to dodge the immune surveillance, secondary to changes in molecular
and cellular pathways necessitated in antigen processing, presentation and degradation of HCC
cells [14–16]. These changes bring a paradigm shift in the immune response from antitumour to
the state of tumour tolerance, leading to genesis and progress of HCC [17–19]. Hence, there is a
great deal of interest in understanding the immunopathogenesis of HCC in order to enhance the
antitumour immune response or inhibit the suppressive effect of immunity as a potential source of
immunotherapy. The present review has aimed to discern the main attributes of the very intricate
and heterogeneous landscape of HCC, pivoting on the dynamic interplay between malignant and
immune cells within the tumour microenvironment. On account of the fact that specific immune
compositions may extend tumour growth, an improved understanding of the functioning of immune
cells and better knowledge of diverse mechanisms of immune evasion will help in formulating various
therapeutic approaches to modulate antitumour immune response in the management of very early
and early-stage HCC tumours.
2. Immune Response and Tolerance in the Hepatic Parenchyma
The hepatic parenchyma performs multitudes of responsibilities such as removal of environmental
or bacterial agents from the alimentary tract, elimination of bloodborne pathogens, and metabolizing
and excreting various toxic substances. Concurrently, hepatic parenchyma has been exposed to loads
of antigens, causing an enormous amount of immune response, which can cause collateral damage to
the normal liver tissue. However, it gets countervailed through the intrinsic mechanism of hepatic
parenchyma to tolerate the immune response [20–22].
The hepatic innate immune system, Kupffer cells, and liver sinusoidal endothelial cells (LSECs)
play an important role in the induction of local immunosuppression [23]. The immune response
includes differentiation of T cells into memory-like T-cells and generation effector T-cells following
reactivation by antigen-presenting cells (APCs) as dendritic cells (DCs) and through activation of
cytotoxic T–cells; however, in the situation of chronic inflammation and ongoing exposure of antigens
induce tolerogenic hepatic priming [24,25]. The priming of hepatic parenchyma manifests with
defective antigen processing by LSECs, undermines antigen-specific immune surveillance and declines
in expression of co-stimulatory molecules B7-1 (CD80) & B7-2 (CD86) on CD4+ T-cells and CD137 on
CD8+ and NK (Natural Killer) cells [26,27].
The CD80 (B7-1) and CD86 (B7-2) molecules present on different types of APCs play essential
roles in the signaling of immune checkpoint pathways B7-CD28/CTLA-4. The interactions of B7
with the CD28 receptor on T-cells relay co-stimulatory signals to antigen-primed T-cells or may
incur co-inhibitory signals following binding with the inhibitory checkpoint receptor, cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) present on T-cells [20,28].
Further, the immunosuppressive role of CTLA-4 has been elucidated through the induction of
immune tolerance in recipient following liver transplantation via expression of CTLA-4 molecule on
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Foxp3+CD25+CD4+ T-regulatory cells (Tregs), which indicates its applicability in the regulation of
immune activity in liver transplantation [29,30].
Additionally, the PD-L1 molecules are present on hepatocytes, hepatic stellate cells (HSCs),
LSECs, and Kupffer cells, which help in the genesis of immune tolerance through induction of T-cell
dysfunction or apoptosis [31,32]. PD-L1/PD-L2/PD-1 (programmed death-ligand 1 or 2/programmed
cell death 1 receptor) immune checkpoint pathway is involved in the inhibition of immune activity in
the hepatic milieu, particularly in instances of chronic inflammation of the liver where the physiologic
expression of PD-L1, along with PD-L2 and PD-1, get enhanced [28,33].
The main purpose of these tolerogenic responses is protection through avoidance of unnecessary
inflammatory response against harmless antigens; however, they become inimical in a situation of
chronic inflammation where immune tolerance to tumor-associated antigens (TAAs) contributes to
onset and progression of HCC (Figure 1).
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by DCs via downregulation of tumour associated antigen (TAA) and MHC molecules; secretion of 
inhibitory factors (IL-10, TGF-b, and VEGF) by tumour and tumour-associated macrophages to rivet 
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Figure 1. Immunological alteration associated with improved antitumour immune response
with the resolution of hepatocellular carcinoma cells. CD: cluster of differentiation; CTLA-4:
cytotoxic T-lymphocyte-associated protein-4; IFNγ: interferon-gamma; IL: interleukin; LAG-3:
lymphocyte-activation gene 3; PD-1: programmed cell death-1; PD-L1: programmed cell death-ligand1;
NK: natural killer cells; TIM-3: T-cell immunoglobulin mucin-3.
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outlined mechanisms employed to alter the antitumour i mune response during the onset of HCC.
The interactive immunosuppressive microenvironment interferes in detection of tumour antigen
by DCs via downregulation of tumour associated a tigen (TAA) and MHC molec les; secretio
of inhibitory factors (IL-10, TGF-b, and VEGF) by tumour and tumour-associated macrophages
to rivet suppressor cells in tumour microenvironment including Tregs cells, TAM, MDSC and
immature DCs; VEGF mediated inhibition of differentiation and function of immune cells during
hematopoiesis; inhibition of helper CD4+ T-cells; ind ction of MDSCs and Tregs secondary to secretion
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of immunosuppressive cytokines and release indoleamine 2,3-dioxygenase (IDO); inhibition of effector
cells through Tregs cells, TAM, and MDSC via production of arginase, ROS, and suppressive cytokines
IL-2 and TGF-b; reduced co-stimulatory molecule expression and activation of inhibitory receptors
(CTLA-4 and PD-1) through its ligands, vitiating release of inflammatory cytokines IL-2, INF-y, TNF and
cytotoxic chemicals perforin and granzyme by CD8+ T-cells [37–40]. On this account, it has been
envisaged that the reinstatement of the antitumour immune response could have the potential of
improving survival and decreasing recurrences in HCC (Figure 2).
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4. HCC Tumour Microenvironment and Changes in Cytokines Milieu
Despite of enhanced levels of expression of neoantigens in HCC tissue and a reciprocal infiltration
of CTLs in tumour tissue, the instigated antitumour immune response is flawed and inadequate [41].
The explicable explanations of diminished immune response include anergy of immune cells secondary
to point mutation or insertion/deletion of β2 microglobulin present in MHC I molecules causing
a defect in antigens presentation to T-cells; expression of inhibitory immune regulatory receptors,
ligands and cytokines such as IL-10 and TGF-b. The immune checkpoints are inhibitory immune
regulatory molecules, which include PD-1, PD-L1, CTLA-4, TIM3, lymphocyte-activating gene 3
protein and other lymphocyte attenuators. CTLA-4 expression on Tregs is associated with a decline in
the production of granzyme B from CTLs, whilst its expression on CD14+ DCs relates with IL-10 and
IDO mediated inhibition of T-cell proliferation with the induction of apoptosis. In addition, lowering of
antitumour immunity is mediated through cells such as Tregs, MDSC and TAM involved in generating
immune tolerance and reduction in hepatic parenchyma infiltrating CD56 dim NK, effector T-cells and
CTLs [42–44].
To achieve optimal antitumor effects, CTLs must not only migrate to the tumour, but also be
competent in functioning to induce lysis of tumour cells. In contrast to the earlier observation that
increased density of lymphocytes within the HCC microenvironment is a surrogate marker of good
prognosis following hepatic resection and transplantation [45]. Recent studies have highlighted that
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despite being the presence of adequate density of lymphocytes within HCC tissue, the antitumour
immune responses are less than apposite owing to the diminution in the capacity for T-cells to
proliferate, to release cytokine and inability to lyse tumour cells [46,47]. The abnormal set of behaviour
can be explained by virtue of reduced CTLs activity secondary to suppressive nature of HCC tumour
microenvironment and failing to release IFNγ upon stimulation of tumour-infiltrating CD8+ T-cells
in contrast to peripheral CD8+ T-cells [48], although the installation of CTLs following isolation and
ex-vivo cultivation has exhibited optimum antitumour specific activity [49]. Further research has
been made to understand the clinical implication of these changes in immunological parameters in
terms of survival. A recent study has outlined poor overall survival in HCC patients with increased
levels of Tregs and reduced intra-tumoural and peripheral CD8+ T-cells [50]. Finkelmeier et al. (2016)
investigated the prognostic value of soluble PD-L1 with HCC and concluded that higher values are
associated with dismal outcomes [51]. Similarly, an increase in levels of immunosuppressive cytokines
(IL-4, IL-5, IL-8 and IL-10) or diminution of stimulating cytokines (IL-1, TNF-a, TFN-y) are also
considered as a marker of poor prognostic value [52–54].
Even though the pathways entailed in HCC associated immune tolerance have not been completely
elucidated, contemporary research has outlined the potential of targeted therapy in the reinstatement
of antitumour immunity through the interaction of receptors, ligands and instigating immune cells
and cytokines level [55].
Tregs cells, one of the important constituents of the HCC tumour microenvironment, cognate
with a reduction in density and functioning of CD8+ T-cells, hence a therapeutic measure targeting
Tregs would not only help in establishing of antitumour immune responses but can also improve
survival [56,57]. Studies have outlined a significant decline in levels of intra-tumoural and circulating
Tregs cells following radiofrequency ablation or radiofrequency based resection of HCC tumour and
an associated improvement in survival [58].
5. HCC Tumour Microenvironment Immunomodulation
5.1. HCC Tumour Microenvironment Immunomodulation through Radiofrequency Application
Contemporary research has demonstrated that the application of radiofrequency (RF) over HCC
nodules not only kills the tumour cells but also releases an abundance of neoantigens and DAMPs,
which, in turn, incites CD8+ T-cell infiltration. The CD8+ T-cells then recognise such antigen-producing
tumour cells alongside metastatic cells. Such immune-mediated response to locoregional therapy
over the tumour nodule was first described in relation to radiation and is known as the “abscopal
effect” [59]. The mechanism behind the abscopal effect has not been completely elucidated; a multitude
of studies have outlined the potential of combining neoantigen generating locoregional therapy
with immunotherapy could further enhance boost such effect. The cellular stress following tumour
irradiation generates tumour-associated antigens (TAAs) secondary to necrosis and apoptosis of
tumour cells and debris similar to vaccine effect with intent to treat or prevent the development of
malignancy [60] (Figure 3). Such effects are observed in various solid tumours, including melanoma,
renal cell carcinoma, hepatocellular carcinoma, to name a few. Further, radiofrequency waves are
similar to radiation, which can elicit a tumour-specific in situ vaccine effect, resulting in a systemic
response. Hence, the application of radiofrequency energy over the HCC tumour facilitates the
release of DAMPs with subsequent increase in peripheral and tumour infiltrating CD4+, CTLs and NK
cells, which shift the scale of balance towards the antitumour immune response rather than cancer
progression [61,62].
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5.2. HCC Tumour Microenvironment Immunomodulation through Immunotherapy
As mentioned earlier and demonstrated in various studies, a mere increase in the levels of
immune cells is not adequate to generate sufficient immune response owing to anergic T-cells. Hence,
immunotherapy targeting co-stimulatory and inhibitory (checkpoint) receptors can reestablish the
T-cell priming and effector functioning back to normal [63]. A targeted approach to modulate the
activity of T-cells includes antagonism of checkpoint inhibitors. Of the various molecules involved
in the immune checkpoint, PD-1, PD-L1 and CTLA-4 have been shown to play important roles in
suppression of T-cell activation by malignant cells [64,65]. On continuance, the development of
monoclonal antibody targeting these molecules has been found to be highly efficacious in cancer with
high immunogenicity, such as malignant melanoma. The last decade has witnessed significant progress
in the understanding of the immune system and led to the development of immune checkpoints
blockades such as anti-CTLA-4, anti-PD-1 and anti-PD-L1, which has shown the potential to bring a
paradigm shift in management and prognosis of several cancers, including liver cancer [55,65].
The expression of CTLA-4 is increased following the activation of T-cells. The interaction between
CTLA-4 and its ligand not only inhibits activity but also inflict anergy to T-cells. The anti-CTLA-4
monoclonal antibodies (tremelimumab and ipilimumab) have demonstrated their ability to deplete
Tregs cells and reverse exhaustion of T-cells with intent to reinstituting the antitumour immune
response. An anti-CTLA-4 monoclonal antibody (tremelimumab) has received FDA approval in 2011
for the treatment of malignant melanoma [66–68].
Similarly, PD-1 and PD-L1 get upregulated following the activation of T-cells and the coupling
of PD-1 with PD-L1 leads to inactivity of T-cells and NK cells functioning. The notable anti-PD-1
(nivolumab and pembrolizumab) and anti-PD-L1 (atezolimumab and avelumab) have further expanded
the applicability of checkpoint inhibitors to various other cancers, including HCC. Presently, several
phase III trials are going on, and the scientific community is eagerly waiting to peruse their outcomes
and explore future applicability [64,69] (Table 1).
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Table 1. Clinical Trials involving various immune checkpoint inhibitors in hepatocellular carcinoma.
Name Study Detail Phase Sample Primary Endpoint Status
CTLA-4
NCT01853618 Tremelimumab with ablation II 32
PR—26%
Median TTP—7.4 mon
Median OS—12.3 mon
Completed
NCT02519348 Tremelimumab with Durvalumab II 144 Safety and tolerability Ongoing
PD-1
NCT01658878 Nivolumab vs. Placebo I/II 262 OR—20%DOR—9.9 mo Completed
NCT02576509 Nivolumab vs. Sorafenib III 726 Overall survival Completed(Results awaited)
NCT02702414 Pembrolizumab vs. Sorafenib II 104 OS—26%Median OS—12.9 mon Completed
NCT02702401 Pembrolizumab vs. Placebo III 408 Progression-free survival,Overall survival Ongoing
NCT03062358 Pembrolizumab vs. Placebo III 330 Overall survival Ongoing
NCT03383458 Nivolumab vs. Placebo III 530 Recurrence-free survival Ongoing
NCT02512773 Tislelizumab vs. Sorafenib III 660 Overall survival Ongoing
PD-L1 NCT03298451
Durvalumab vs.
Durvalumab + Tremelimumab (regimen 1) vs.
Durvalumab + Tremelimumab (regimen 2) vs.
Sorafenib
III 1200 Overall survival Ongoing
NCT03434379 Atezolizumab + Bevacizumab vs. Sorafenib III 480 Overall survival Ongoing
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A phase II, non-controlled trial evaluated tremelimumab, a humanised IgG2 monoclonal antibody
against CTLA-4 in advanced HCC patients not eligible for surgery or locoregional therapy. A total
of 21 patients with advanced HCC with chronic HCV infection and Child–Pugh scores A (57.1%) or
B (42.9%) were enrolled. Each patient received 15 mg/kg of tremelimumab every 90 days as a single
agent therapy. A partial response was observed in 17.6% with a disease control rate of 76.4% and
a median overall survival of 8.2 months. Approximately 45% had transient grade 3 transaminase
toxicity following initial dosing of tremelimumab dose, although it did not require systemic steroids.
A progressive decline in viral load was observed most of the patients, but a complete viral response
was reported in just 3 patients. The analysis of results indicates a dual effect of tremelimumab in terms
of antitumour and antiviral activity, suggesting that immune checkpoint treatment can be particularly
beneficial in patients with a viral etiology such as HBV or HCV-related HCC [70].
A phase I/II trial studied the safety and preliminary activity of anti-PD-1 antibody nivolumab
(humanised IgG4 monoclonal antibody) in 262 advanced HCC patients with or without HBV or HCV
infection received 0.1–10 mg/kg of nivolumab once every 2 weeks (dose-escalating cohort) or at a
dose level of 3 mg/kg once every 2 weeks (expansion cohort). The trial demonstrated a manageable
safety profile with a promising efficacy (dose-escalation cohort: response rate of 15%, median survival
period of 15 months; expansion cohort: response rate of 20%, duration of response 9.9 months [71].
Further phase III randomised trial (NCT02576509) has compared nivolumab against sorafenib for
unresectable HCC as a first-line treatment but did not outline any significant difference in terms of
overall survival (HR, 0.85; 95% CI, 0.72–1.02; p = 0.0752); however, further details of analysis by
study group are still awaited [72]. Another ongoing trial NCT03383458 is evaluating the efficacy of
nivolumab as adjuvant therapy following surgical resection or ablation for HCC tumours [73].
Another phase II trial (KEYNOTE-224, NCT02702414) with anti-PD-1pembrolizumab reported
overall response rate (18%) and median survival of 12.9 months in advanced HCC following failed
sorafenib treatment. In light of these promising results, the US FDA granted approval to nivolumab
and pembrolizumab for treating HCC in patients who had received prior sorafenib, while many other
immune checkpoint inhibitors are under evaluation to determine their applicability for treatment in
HCC [74] (Table 1).
Studies have advocated that combining anti-CTLA-4 with anti-PD-1/PD-L1 could produce
a superlative approach in reestablishing a competent immunity through the mitigation of
immunosuppression signals. The interaction of CTLA-4 on T-cells with B7 ligands expressed on DCs
or APCs in lymph node limits number and activity T-cells, whereas binding of PD-1 expressed on the
activated CTLs to its ligand PD-L1 on tumour cells or TAM, brings inactivity of T-cells [75,76]. Hence,
the rationale of combining includes induction of T-cells proliferation through inhibition of CTLA-4 and
enhance CTLs activity through PD-1 inhibition.
A phase I/II trial assessed the combination of anti-PD-L1 antibody (durvalumab) and anti-CTLA-4
antibody (tremelimumab) in 40 patients with advanced HCC and demonstrated a response rate of
25%; highlighting the benefit of combined approach over monotherapy with tolerable toxicity profile.
Presently, phase III trial (NCT03298451) is evaluating the efficacy of various regimens, including
durvalumab monotherapy with two regimens of durvalumab and tremelimumab combination and
sorafenib monotherapy. Another ongoing trial (NCT01658878) is assessing the efficacy of combination
nivolumab with ipilimumab in contrast to nivolumab alone [74,77].
5.3. HCC Tumour Microenvironment Immunomodulation through Combined Approach
Contemporary research has demonstrated locoregional therapy, particularly radiofrequency (RF)
based ablation of HCC nodules, not only kills the tumour cells but also release an abundance
of neoantigens and DAMPs and induce CD8+ T-cell infiltration. According to meta-analysis
performed by Ding et al., increased density of tumour infiltrating lymphocytes (TILs) have been
significantly associated with improved survival [78]. Additionally, studies have outlined positive
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immunomodulatory change following the application of RF in terms of Tregs, CD8+ T-cells, TGF-β,
IFNγ, IL-10, IL-17, respectively [79–82].
Further, Tumeh et al. (2014) demonstrated that better tumour response following introduction
pembrolizumab in a situation of higher expression of PD-1/PD-L1 on CD8+ T-cells at the margin
of melanoma tumours. In addition, observation of significant tumour regression was discerned
in association with an increase in CD8+ T-cells from baseline to post-treatment biopsy, specifically
at the tumour center and invasive margin. Hence, both baseline and post-treatment CD8+ T-cells
may act as important biomarkers in envisaging the tumour response to checkpoint inhibitors [83].
The combined approach involves radiofrequency ablation to generate neoantigens and influx of CD8+
T-cells, along with checkpoint inhibitors to activate these CD8+ T-cells to invigorate an antitumour
immune response against HCC cells. Here, RF-induced cellular stress generates tumour-associated
antigens (TAAs) through necrosis and apoptosis, which act as vaccines to activate the antitumour
immune response, which gets boosted with the simultaneous introduction of checkpoint inhibitors
with intent to treat or prevent the development of malignancy and distant metastasis (Figure 4).
The same principle has formed the basis of a recent trial done by Duffy et al. (2017), where they
evaluated 19 patients of advanced HCC to understand the clinical response of combining ablation with
anti-CTLA-4 (tremelimumab). Five (26.3%) of nineteen had a partial response (95% confidence interval,
9.1–51.2%); 12 out of 14 HCC patients also marked quantifiable reduction in HCV viral load following
treatment [84]. The plausible explanation of the observed decline in viral load could be because of
the simultaneous return of immune response against these hepatotropic viruses too. Although the
observed findings are intriguing and require further studies to envisage future applicability.
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Immune checkpoint inhibitors are proved to be beneficial in the treatment of advanced HCC;
however, the world of immunomodulation is still not fully explored, particularly in very early and
early stages of HCC. oreover, the identification of predictive markers is of the utmost importance
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to determine a subgroup of HCC patients who are most likely to be benefitted from checkpoint
inhibitors. Research exploring predictive markers for checkpoint treatment response has pointed
towards mutational burden, PD-L1 expression, expression of immune regulatory molecules and
epithelial-to-mesenchymal transition (EMT) [85,86]. Shrestha et al. (2018) [87] reported that HCC
patients with higher mutation burden have significantly poor overall survival and progression-free
survival than those with a lower mutation burden; however, a study by Mauriello et al. [88] highlighted
that high mutation does not correlate with a decline in survival in the absence of immunotherapy.
On the contrary, multiple studies have shown that a high mutation burden associated with a better
response to checkpoint inhibitors in melanoma patients. The mechanism is not fully understood,
but an increased number of neoantigens (potential tumor-specific T-cell targets) generated by a high
mutation burden is thought to bring an enhanced response from checkpoint inhibitors. Similarly,
PD-L1 expression in HCC has been reported as a predictive biomarker for poor prognosis and can also
utilised as an important tool to predict the response to anti-PD-1 antibodies; however, identifying other
immune biomarkers could play an important role to further improve patient outcome as PD-L1 levels
fluctuate along the course of the disease and only expressed in 30% of HCC tumours [89]. Higher levels
of PD-L1 induce EMT in HCC patients with an increase in invasion and metastasis of malignant
cells [87,90]. Thus, HCC patients with EMT phenotype are more likely to respond to PD-1/PD-L1
targeted immunotherapy.
6. Future Perspectives and Conclusions
Despite advancement in chemotherapy, the observed outcomes in advance HCC tumours
are dismal owing to reduced immune recognition of cancer cells and the development of an
immunosuppressive microenvironment, rendering the immune system unable to mount an effective
antitumour response. The present review has outlined the tumour microenvironment in HCC and
summarised the applicability of checkpoint inhibitors and their potential benefits in terms of partial
response, reduction in viral load and improved survival in advanced HCC. The same principle could
be applicable in very early stages of HCC, where radiofrequency ablation or radiofrequency based
resection in early stages to generate neoantigens to reinstate antitumor immunity, which could be
boosted with checkpoint inhibitors. The mechanisms behind the diverse clinical responses to mono or
a combined regimen of checkpoint inhibitors in advanced HCC patients are insufficiently elucidated.
A focus on functional evaluations in the context of patient immunity for novel regimens alongside
clinical testing may shed some light on the most effective combinations and the best strategies to
reduce adverse effects. However, because of the complexity of the antitumour immune response
and the observed heterogeneity, it is improbable to predict wide-ranging clinical benefits without
using a wide set of biomarkers. Biomarker development is an area of intense study and remains a
considerable clinical challenge. A few notable markers for checkpoint treatment response include
the degree of mutational burden, PD-L1 expression, expression of immune regulatory molecules and
EMT phenotype; however, further studies are warranted to develop better strategies with checkpoint
inhibitors in HCC along with biomarkers in very early and early stages.
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